Cuba’s Centre for Molecular Immunology (CIM) has patented a new therapeutic lung cancer vaccine, according to Ana Maria Vazquez, a specialist at the institution.

Vazquez said on Monday that the antibody, called Racotumomab, was proven in rigorous clinical trials in 2012 to increase survival rates among cancer patients, and has shown good safety and tolerance levels.

The new vaccine reportedly combats lung carcinoma by reducing cancer cells and minimizing the presence of tumours.

CLICK HERE TO READ FULL STORY